Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Novartis Pharmaceuticals · 2022
ClinicalTrials.gov · Datasets · License: Public Domain · 2022
Open Source ↗
systemic-lupus-erythematosus
lupus nephritis, lnp023, iptacopan, proteinuria, urine protein-to-creatinine ratio, complete renal response, estimated glomerular filtration rate, renal flares, systemic lupus erythematosus, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 870100
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.